Pfizer (NYSE:PFE) has faced significant challenges in recent years, with the stock losing half its value since late 2021 as COVID-19 vaccine demand waned. The pharmaceutical giant has struggled to ...

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...

Pfizer shares are now trading at pre-Covid levels, presenting a significant buying opportunity. The company has built up a strong cash reserve since Covid, allowing for accelerated R&D, the Seagen ...

Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. The 6.7% ...